SG
CSCI

StoneX Group’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

StoneX Group’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150
Closed -$2.95K – 537
2022
Q2 		$2.95K Buy
+150
New +$3.75K ﹤0.01% 494

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

StoneX Group's CSCI Position: Q3 2022 in Review

StoneX Group sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2022, closing a stake of 150 shares — an estimated $2.95K sold.

StoneX Group first reported a position in CSCI in Q2 2022 and held it in 1 quarter. The position peaked at $2.95K in Q2 2022. 12 funds tracked by Wall St. Rank hold CSCI as of Q3 2022.

  • StoneX Group reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • StoneX Group sold 150 COSCIENS Biopharma Inc. Common Stock shares in Q3 2022, an estimated $2.95K.
  • StoneX Group first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • StoneX Group's COSCIENS Biopharma Inc. Common Stock position peaked at $2.95K in Q2 2022.
  • 12 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.